231 related articles for article (PubMed ID: 12855626)
1. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.
Adjei AA; Croghan GA; Erlichman C; Marks RS; Reid JM; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Bruzek LM; Atherton P; Thibault A; Palmer PA; Kaufmann SH
Clin Cancer Res; 2003 Jul; 9(7):2520-6. PubMed ID: 12855626
[TBL] [Abstract][Full Text] [Related]
2. A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
Chow LQ; Eckhardt SG; O'Bryant CL; Schultz MK; Morrow M; Grolnic S; Basche M; Gore L
Cancer Chemother Pharmacol; 2008 Sep; 62(4):631-46. PubMed ID: 18058098
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors.
Punt CJ; van Maanen L; Bol CJ; Seifert WF; Wagener DJ
Anticancer Drugs; 2001 Mar; 12(3):193-7. PubMed ID: 11290865
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.
Cohen SJ; Gallo J; Lewis NL; Alpaugh RK; Gentner L; Rogatko A; Yeslow G; Schol J; Verhaeghe T; Zannikos P; Palmer PA; Weiner LM; Meropol NJ
Cancer Chemother Pharmacol; 2004 Jun; 53(6):513-8. PubMed ID: 14760509
[TBL] [Abstract][Full Text] [Related]
5. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.
Zujewski J; Horak ID; Bol CJ; Woestenborghs R; Bowden C; End DW; Piotrovsky VK; Chiao J; Belly RT; Todd A; Kopp WC; Kohler DR; Chow C; Noone M; Hakim FT; Larkin G; Gress RE; Nussenblatt RB; Kremer AB; Cowan KH
J Clin Oncol; 2000 Feb; 18(4):927-41. PubMed ID: 10673536
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours.
Siegel-Lakhai WS; Crul M; Zhang S; Sparidans RW; Pluim D; Howes A; Solanki B; Beijnen JH; Schellens JH
Br J Cancer; 2005 Nov; 93(11):1222-9. PubMed ID: 16251868
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer.
Adjei AA; Mauer A; Bruzek L; Marks RS; Hillman S; Geyer S; Hanson LJ; Wright JJ; Erlichman C; Kaufmann SH; Vokes EE
J Clin Oncol; 2003 May; 21(9):1760-6. PubMed ID: 12721252
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.
Crul M; de Klerk GJ; Swart M; van't Veer LJ; de Jong D; Boerrigter L; Palmer PA; Bol CJ; Tan H; de Gast GC; Beijnen JH; Schellens JH
J Clin Oncol; 2002 Jun; 20(11):2726-35. PubMed ID: 12039935
[TBL] [Abstract][Full Text] [Related]
10. Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors.
Galsky MD; Posner M; Holcombe RF; Lee KM; Misiukiewicz K; Tsao CK; Godbold J; Soto R; Gimpel-Tetra K; Lowe N; Oh WK
Cancer Chemother Pharmacol; 2014 Sep; 74(3):465-71. PubMed ID: 25023489
[TBL] [Abstract][Full Text] [Related]
11. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
Kurzrock R; Kantarjian HM; Cortes JE; Singhania N; Thomas DA; Wilson EF; Wright JJ; Freireich EJ; Talpaz M; Sebti SM
Blood; 2003 Dec; 102(13):4527-34. PubMed ID: 12947010
[TBL] [Abstract][Full Text] [Related]
12. A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
Patnaik A; Eckhardt SG; Izbicka E; Tolcher AA; Hammond LA; Takimoto CH; Schwartz G; McCreery H; Goetz A; Mori M; Terada K; Gentner L; Rybak ME; Richards H; Zhang S; Rowinsky EK
Clin Cancer Res; 2003 Oct; 9(13):4761-71. PubMed ID: 14581347
[TBL] [Abstract][Full Text] [Related]
13. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.
Zhu K; Gerbino E; Beaupre DM; Mackley PA; Muro-Cacho C; Beam C; Hamilton AD; Lichtenheld MG; Kerr WG; Dalton W; Alsina M; Sebti SM
Blood; 2005 Jun; 105(12):4759-66. PubMed ID: 15728126
[TBL] [Abstract][Full Text] [Related]
14. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
Karp JE; Lancet JE; Kaufmann SH; End DW; Wright JJ; Bol K; Horak I; Tidwell ML; Liesveld J; Kottke TJ; Ange D; Buddharaju L; Gojo I; Highsmith WE; Belly RT; Hohl RJ; Rybak ME; Thibault A; Rosenblatt J
Blood; 2001 Jun; 97(11):3361-9. PubMed ID: 11369625
[TBL] [Abstract][Full Text] [Related]
15. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
Voortman J; Smit EF; Honeywell R; Kuenen BC; Peters GJ; van de Velde H; Giaccone G
Clin Cancer Res; 2007 Jun; 13(12):3642-51. PubMed ID: 17575229
[TBL] [Abstract][Full Text] [Related]
16. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.
Rajan A; Carter CA; Kelly RJ; Gutierrez M; Kummar S; Szabo E; Yancey MA; Ji J; Mannargudi B; Woo S; Spencer S; Figg WD; Giaccone G
Clin Cancer Res; 2012 Apr; 18(8):2344-51. PubMed ID: 22371451
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma.
Rosenberg JE; von der Maase H; Seigne JD; Mardiak J; Vaughn DJ; Moore M; Sahasrabudhe D; Palmer PA; Perez-Ruixo JJ; Small EJ
Cancer; 2005 May; 103(10):2035-41. PubMed ID: 15812833
[TBL] [Abstract][Full Text] [Related]
18. A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors.
Mackay HJ; Hoekstra R; Eskens FA; Loos WJ; Crawford D; Voi M; Van Vreckem A; Evans TR; Verweij J
Clin Cancer Res; 2004 Apr; 10(8):2636-44. PubMed ID: 15102665
[TBL] [Abstract][Full Text] [Related]
19. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies.
Karp JE
Semin Hematol; 2001 Jul; 38(3 Suppl 7):16-23. PubMed ID: 11523024
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.
Cortes J; Albitar M; Thomas D; Giles F; Kurzrock R; Thibault A; Rackoff W; Koller C; O'Brien S; Garcia-Manero G; Talpaz M; Kantarjian H
Blood; 2003 Mar; 101(5):1692-7. PubMed ID: 12411300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]